Get to know our clinical trials
Study of RO7247669, a bispecific antibody against pd1-lag3, in patients with advanced and/or metastatic solid tumors.
THE MAIN OBJECTIVE OF THIS STUDY IS TO DETERMINE THE SAFETY, TOLERABILITY, MAXIMUM TOLERATED DOSE (MTD) AND/OR RECOMMENDED DOSE FOR PHASE II (DRF2) OF RO7247669 ADMINISTERED INTRAVENOUSLY (IV) IN MONOTHERAPY.
Technical Summary
- MULTICENTER, OPEN-LABEL, DOSE-ESCALATION PHASE I STUDY TO EVALUATE THE SAFETY/TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND PRELIMINARY ANTITUMOR ACTIVITY OF RO7247669, A BISPECIFIC ANTIBODY AGAINST PD1-LAG3, IN PATIENTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS
- Code EudraCT: 2019-000779-18
- Protocol number: NP41300
- Promoter: F. Hoffmann-La Roche Ltd.
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.